TriangleONC201 (NCT05009992)
ONC201 trial for Diffuse Intrinsic Pontine Glioma (NCT05009992). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged two to thirty-nine with diffuse midline glioma. Open cohort five requires specified molecular changes; cohort six requires newly diagnosed thalamic or pontine disease without progression after radiation.
The idea: cohort five pairs oral ONC201 with molecularly selected drugs. Cohort six injects DNX-2401, a virus designed to destroy tumor cells, directly into tumors, with biopsies. Cohorts one through four are closed. Eligibility and treatment differ between groups.
This phase 2 study plans 360 patients. Sabine Mueller leads at UCSF, San Francisco; nineteen US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.